[Diagnosis and differentiated treatment of secondary immunodeficiencies].
OBJECTIVE
To evaluate alterations in the immune system (IS) in patients with different forms of secondary immunodeficiency and design of differentiated programs of reestablishment of defective functions depending on pathogenetically important type of deficiency of immunocompetent cells.


METHODS
Clinicoimmunological examination was made in 678 patients with complicated course of infectious-inflammatory diseases. Immunotropic medicines and physicochemical impacts were used in accordance with types of disorders in the system of immune homeostasis.


RESULTS
There was a pathogenetic heterogeneity of IS disorders in complicated course of infectious-inflammatory diseases: generalized forms of infection (bacterial shock, sepsis) are in 75% of cases associated with deficiency of effector functions of peripheral blood polymorphonuclear leukocytes of the second-third degree, progressive fall in production of IgG immunoglobulins (42%), cellular-humoral immunodeficiency (92%). In lingering acute inflammatory diseases activation of phagocytosis occurred in 30%, IgG and/or IgM rise was in 50%, phagocytic function deficiency occurred in 48%, low production of immunoglobulins in 24%, humoral-cellular immunodeficiency in 62%. Purulent infection is associated with secondary cellular-humoral immunodeficiency, lowering of the immunoregulatory index (47%), phagocytic function deficiency (up to 35%), hyperproduction of IgM. Recurrent bacterial-viral diseases form in immunocompromised patients with T-lymphocytopenia (56%) and cellular-humoral immunodeficiency (30%).


CONCLUSIONS
Protracted chronic inflammatory diseases are characterized by variability of changes in the immune systems. Combined types of disorders were found in 52% of the examinees. Pathogenetic heterogeneity of the disorders are determined by concomitant and previous diseases, occupational hazards and intoxication, environmental conditions, etc.


CONCLUSIONS
Immunocorrective therapy in secondary immunodeficiency is conducted with allowances for pathogenetically essential types of disorders in the system of immune homeostasis, clinical variant of complication of inflammatory process under control of immunogram.
Kolesnikov
A P
AP
Khabarov
A S
AS
Kozlov
V A
VA
D000208:Acute Disease; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use; D000917:Antibody Formation; D015415:Biomarkers; D001991:Bronchitis / Q000276:immunology; D002908:Chronic Disease; D016207:Cytokines / Q000008:administration & dosage / Q000627:therapeutic use; D004338:Drug Combinations; D019084:Fluorescent Antibody Technique, Indirect; D006706:Homeostasis; D006801:Humans; D007111:Immunity, Cellular; D016867:Immunocompromised Host; D007136:Immunoglobulins / Q000172:deficiency; D007153:Immunologic Deficiency Syndromes / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use; D007239:Infections / Q000276:immunology*; D007249:Inflammation / Q000276:immunology*; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use; D009842:Oligopeptides / Q000008:administration & dosage / Q000627:therapeutic use; D010585:Phagocyte Bactericidal Dysfunction / Q000276:immunology; D010586:Phagocytes / Q000276:immunology; D011014:Pneumonia / Q000276:immunology; D012008:Recurrence; D012397:Rosette Formation; D012772:Shock, Septic / Q000276:immunology; D013492:Suppuration / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors; D014777:Virus Diseases / Q000276:immunology
D000276:Adjuvants, Immunologic; D015415:Biomarkers; D016207:Cytokines; D004338:Drug Combinations; D007136:Immunoglobulins; D007155:Immunologic Factors; D007370:Interferon Type I; D009842:Oligopeptides; C062252:leukinferon; C080035:thymohexin; C048617:myelopeptides